Eli Lilly to Buy Atai Beckley for $2.8 Billion
2026-07-16 11:16:07
Eli Lilly said on July 16 that it has reached a definitive agreement to acquire clinical-stage biopharmaceutical company Atai Beckley for $6.75 in cash per share, valuing the equity at about $2.8 billion. According to 36Kr, shareholders could also receive up to $2.50 per share in contingent value rights if two psychiatric drug candidates hit specified development and regulatory milestones, which would add about $1 billion in potential equity value. The deal is expected to close in the third quarter of this year, pending shareholder and regulatory approval.
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
